Trial Profile
Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 23 Mar 2021 Status changed from recruiting to completed.
- 17 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Aug 2018.
- 27 Jun 2018 New trial record